|
**Overview**: Growth Disorder Panel**Introduction**: The Growth Disorder Panel is a diagnostic tool designed to assess growth disorders using serum samples. In India, short stature affects ~3-5 percent of children, often due to growth hormone deficiency, hypothyroidism, or chronic illness, with underdiagnosis in rural/low-SES populations leading to lifelong short stature and psychosocial issues. High morbidity from delayed GH therapy or thyroid treatment. Per endocrinology practices aligned with ICMR and Indian Society for Pediatric and Adolescent Endocrinology guidelines, the test employs immunoassay for IGF-1, growth hormone, and TSH over 1-2 days with high accuracy, valuable for initial evaluation of growth failure. This diagnostic falls under hormonal screening and targets children with short stature or poor growth velocity, addressing accurate detection to guide GH stimulation tests or levothyroxine. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise hormonal assessment and improving height outcomes. Its serum-based approach ensures reliable measurement.**Other Names**: Growth Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.**Historical Milestone**: IGF-1/GH/TSH panel standard; in India, used in pediatric clinics.**Purpose**: The test assesses 3 parameters including IGF-1 to guide growth disorder evaluation, detect hormonal deficiencies, inform therapy.**Test Parameters**: 1. IGF-1, 2. Growth Hormone, 3. TSH.**Pretest Condition**: No fasting required; patients should report short stature or poor growth.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on growth velocity, puberty, family height.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated growth disorder including short stature, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or age/puberty stage can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low IGF-1/GH indicates deficiency, necessitating specialist input. Abnormal TSH suggests hypothyroidism.**Specialist Consultation**: Pediatric endocrinologists should be consulted for management.**Additional Supporting Tests**: GH stimulation, bone age X-ray for confirmation.**Test Limitations**: Requires clinical correlation; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Growth Studies India 2023. |
